Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian)
- Generic Name
- Recombinant anti-IL-5 humanized monoclonal antibody (Shanghai CP Guojian)
A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2024-11-08
- Target Recruit Count
- 225
- Registration Number
- NCT06680947
Efficacy and Safety Study of 610 in Patients With Severe Asthma
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Target Recruit Count
- 480
- Registration Number
- NCT06323213
Safety, Tolerability and Pharmacokinetic of Recombinant Anti-IL-5 Humanized Monoclonal Antibody Injection
Phase 1
- Conditions
- add-on Maintenance Treatment of Patients With Severe Eosinophilic Asthma
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2021-01-28
- Target Recruit Count
- 52
- Registration Number
- NCT04445038
- Locations
- 🇨🇳
Shanghai General Hospital, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath